Skip to main content
. 2021 Jun 5;74(5):882–890. doi: 10.1093/cid/ciab515

Table 3.

Weighted Proportion of Prevalence of SARS-CoV-2 Stratified by Medical History: Kinshasa, Democratic Republic of the Congo, 2020

Participants
Seropositivea Indeterminateb Seronegative
Participants Tested, n n (%) 95% CI (%) n (%) 95% CI (%) n (%) 95% CI (%)
Number of symptoms
 None 324 54 (18.0) 13.3–23.8 48 (15.5) 11.2–21.1 222 (66.5) 59.8–72.6
 1 to 2 symptoms 266 42 (16.7) 11.9–22.8 57 (21.2) 15.9–27.7 167 (62.1) 54.9–68.8
 3 to 5 symptoms 236 38 (17.5) 12.3–24.2 43 (17.7) 12.6–24.2 155 (64.8) 57.2–71.7
 ≥5 symptoms 239 30 (13.8) 9.2–20.2 35 (14.1) 9.6–20.2 174 (72.1) 64.7–78.4
Symptoms
 Fever
  No 692 113 (17.6) 14.3–21.3 123 (18.1) 14.9–21.9 456 (64.3) 59.9–68.5
  Yes 388 54 (14.8) 11.0–19.8 62 (15.3) 11.5–20.1 272 (69.9) 64.1–75.1
 Chills
  No 829 142 (18.3) 15.3–21.8 147 (17.7) 14.7–21.0 540 (64.0) 60.0–67.9
  Yes 244 24 (11.2) 7.1–17.1 37 (15.3) 10.6–21.7 183 (73.5) 66.2–79.7
 Fatigue/asthenia
  No 844 132 (16.6) 13.8–20.0 152 (17.7) 14.9–21.0 560 (65.6) 61.7–69.4
  Yes 232 34 (16.4) 11.3–23.3 32 (14.7) 9.9–21.3 166 (69.9) 61.1–75.7
 Muscle pain (myalgia)
  No 832 118 (14.6) 11.9–17.8 148 (17.9) 15.0–21.3 566 (67.5) 63.6–71.2
  Yes 240 48 (23.7) 17.6–31.1 36 (14.7) 10.1–20.9 156 (61.7) 53.9–68.9
 Sore throat
  No 941 148 (17.0) 14.2–20.2 158 (16.7) 14.0–19.8 635 (66.3) 62.5–69.8
  Yes 139 19 (14.0) 8.4–22.4 27 (19.7) 13.0–28.8 93 (66.3) 56.3–75.0
 Cough
  No 791 128 (17.2) 14.2–20.7 133 (17.0) 14.1–20.5 530 (65.7) 61.6–69.6
  Yes 289 39 (14.8) 10.4–20.7 52 (17.7) 12.7–23.2 198 (67.8) 61.0–74.0
 Runny nose (rhinorrhea)
  No 770 122 (16.7) 13.7–20.2 138 (18.2) 15.2–21.8 510 (65.1) 60.9–69.0
  Yes 310 45 (16.3) 11.8–22.1 47 (14.3) 10.3–19.5 218 (69.4) 62.9–75.3
 Breathing difficulties
  No 1037 163 (16.9) 14.3–19.9 176 (16.9) 14.3–19.9 698 (66.2) 62.6–69.5
  Yes 43 4 (8.2) 2.6–23.4 9 (22.5) 10.8–40.9 30 (69.3) 51.0–83.0
 Loss of taste and smell (ageusia/anosmia)
  No 929 144 (16.7) 13.9–19.9 162 (14.5) 14.7–20.6 623 (65.9) 62.1–69.5
  Yes 141 23 (16.1) 10.2–24.5 23 (15.3) 9.7–23.3 105 (68.6) 59.2–76.7
 Chest pain
  No 849 160 (16.8) 14.2–19.9 171 (16.8) 14.2–19.8 678 (66.4) 62.7–69.8
  Yes 160 7 (13.3) 6.0–27.2 14 (21.4) 12.1–25.0 50 (65.3) 50.9–77.3
 Other respiratory symptoms
  No 1066 12 (16.6) 14.0–19.5 182 (17.1) 14.5–20.0 719 (66.3) 62.8–69.6
  Yes 14 2 (15.4) 3.3–49.0 3 (21.4) 5.9–54.3 9 (63.2) 32.5–86.0
 Anorexia
  No 917 146 (16.8) 14.1–20.0 162 (17.8) 15.0–21.0 609 (65.4) 61.6–69.0
  Yes 163 21 (15.4) 9.6–23.7 23 (13.3) 8.3–20.7 119 (71.3) 62.2–79.0
 Headache
  No 690 108 (17.2) 13.9–21.0 121 (17.5) 14.3–21.2 461 (65.3) 60.9–69.5
  Yes 390 59 (15.6) 11.7–20.4 64 (16.4) 12.5–21.3 267 (68.0) 62.2–73.3
 Nausea/vomiting
  No 959 156 (17.4) 14.7–20.6 159 (16.6) 14.0–19.7 644 (66.0) 62.3–69.5
  Yes 121 11 (9.7) 4.9–18.3 26 (21.5) 14.0–31.6 84 (68.8) 58.1–77.9
 Abdominal pain
  No 862 193 (17.6) 14.7–21.0 146 (17.1) 14.2–20.3 574 (65.3) 61.4–69.1
  Yes 218 25 (12.3) 7.8–18.8 39 (17.5) 12.2–24.3 154 (70.3) 62.4–77.0
 Diarrhea
  No 956 103 (16.5) 13.8–19.6 161 (16.9) 14.2–19.9 649 (66.7) 63.0–70.2
  Yes 124 21 (17.6) 10.9–27.1 24 (19.1) 12.2–28.7 79 (63.3) 52.8–72.7
Hospitalization
 No 1024 153 (16.0)c 13.4–19.0 177 (17.3) 14.7–20.3 694 (66.7) 38.6–70.0
 Yes 52 14 (29.8)c 17.0–46.8 8 (15.5) 7.0–30.7 30 (54.8) 63.1–70.1

Abbreviations: CI, confidence interval; SARS-CoV-2, severe acute respiratory syndrome coronavirus 2.

aPresence of antibodies to nucleocapsid and spike proteins.

bPresence of antibodies to only nucleocapsid or spike protein.

cSignificant difference at 5%.